Luca Biasco

WORK HISTORY

EDUCATION

ABOUT LUCA BIASCO

21 years academic/industry experience in Gene Therapy and Hematology.I am known as a pioneer of clonal tracking of genetically engineered hematopoietic/stem progenitor cells and T cells in humans and on in vivo engineering of HSPC. As academic and industry research lead, I have authored several publications in high-impact scientific journals such as Science, Nature Biotechnology, Nature Medicine, Nature Cancer and Cell Stem Cell and I have been the recipient of 5 major international awards in Gene Therapy and Hematology. I hold several patent on hematopoietic stem cell identification purification, as well as on in vivo delivery system based on lentiviral vectors (LV) and viral-like particles (VLP). Main research accomplishment• Designed a clonal tracking system based on viral insertion sites analysis to track the fate of engineered cells in vivo in humans• Unveiled the engraftment dynamics, survival and activity of transplanted engineered HSC and T cells in humans• Generated the highest resolution transcriptional map of adult human hematopoietic stem/progenitor stages and unveiled the origin of the baso/eosinophil branching• Established state-of-the-art in vivo engineering of human hematopoietic stem cells with LV and VLPShort BioI graduated in Medical Biotechnology in 2003 at University of Bologna, Italy and moved to Milan to join the San Raffaele Telethon Institute of Gene Therapy where I obtained my PhD in cellular and molecular biology in 2010. I became later a group leader specializing in the study of LV vector-host interactions. In this period, I generated the safety data for the marketing authorization of Strimvelis™, the first commercially approved ex vivo stem cell gene therapy in the world. In 2016 I moved to Boston MA, US as Assistant Professor at Harvard Medical School where I directed the vector safety team for the Gene Therapy program at Boston Children\'s Hospital. My lab worked on understanding the properties of stem cell gene therapy products and their in vivo dynamics in humans. Over the same period, I was appointed Senior Research Associate and then Visiting Professor at UCL, in London UK where I am conducting translational research on immunodeficiencies and CAR-T cells. In 2019 I joined AVROBIO Inc. as Director of R&D where I applied single cell molecular analyses to track the fate and activity of genetically engineered cells in clinical trials. During 2022-23 I led the in vivo HSC Gene Therapy project at SANA Biotechnology. During 2024-25 I was Vice President of Preclinical Research (in vivo gene delivery) at nChroma Bio.